Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313729 · ClinicalTrials.gov registry record · Phase 2
Temozolomide in Treating Patients With Low-Grade Glioma
A Phase 2 study of CNS Tumor, Adult, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT00313729 is a Phase 2 study of CNS Tumor, Adult that has completed, run by University of California, San Francisco. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00313729, a Phase 2 study of CNS Tumor, Adult, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with supratentorial low-grade glioma.
Conditions Studied
Interventions
- DRUG temozolomide
Study Locations (1)
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 1999-05 |
| Est. Completion | 2017-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313729
The ClinicalTrials.gov registry entry for NCT00313729 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CNS Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which temozolomide is the first listed.
NCT00313729 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00313729 about?
NCT00313729 is a clinical study titled "Temozolomide in Treating Patients With Low-Grade Glioma". RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with supratentorial low-gra...
What is the current status of trial NCT00313729?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 1999-05. Estimated completion is 2017-06-12.
What conditions does trial NCT00313729 study?
This clinical trial studies the following conditions: CNS Tumor, Adult.
What interventions are being tested in trial NCT00313729?
The interventions under investigation include: temozolomide (DRUG).
Who is sponsoring clinical trial NCT00313729?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00313729 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CNS Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.